Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 11086 participants.

Also called NCT05845489

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 11,086 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05845489
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05845489. Randomized; no masking; primary purpose prevention. Start 2023-03-22 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
Intervention (Drug)
Clopidogrel treatment group
Intervention (Other)
No antiplatelet or anticoagulant group
Lead sponsor
Seoul National University Hospital (class: other)
Collaborator
Samjin Pharmaceutical Co., Ltd. (class: industry)
Collaborator
CKD Pharmaceutical Limited (class: not stated)
Collaborator
Hanmi Pharmaceutical co., ltd. (class: other)
Collaborator
Yuhan Pharmaceutical Company (class: not stated)
Collaborator
Daewoong Pharmaceutical Co. LTD. (class: industry)
Collaborator
Dong-A ST Co., Ltd. (class: industry)
Collaborator
IlDong Pharmaceutical Co Ltd (class: industry)

Record details

Record id
cardio:ct-nct05845489
Content hash
de78243bf711578da1f6d19ca61e102e404aa8ca73d54a9330ab3c7cf1435305